
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Polymyositis and dermatomyositis diagnostic study of choice
Introduction
Overview
Overview
Muscle biopsy is the gold standard test for the diagnosis of polymyositis and dermatomyositis. Necrosis, increase in endomysial and perimysial connective tissue, atrophy and degeneration of both type I and II fibers, especially in a perifascicular distribution might be seen in muscle biopsy. The muscle biopsy should be performed when a patient presented with symptoms of muscle weakness and skin rash or elevated level of muscle enzymes.
Diagnostic Study of Choice
Diagnostic Study of Choice
- Muscle biopsy is the gold standard test for the diagnosis of polymyositis and dermatomyositis.[1][2][3][4][5]
- The following result of muscle biopsy is confirmatory of polymyositis and dermatomyositis:
- Necrosis
- Phagocytosis
- Regenerative activity reflected by basophilia, large, vesicular nuclei and prominent nucleoli
- Atrophy and degeneration of both type I and II fibers, especially in a perifascicular distribution
- Internal migration of nuclei
- Vacuolization
- Fiber-size variation
- Mononuclear inflammatory infiltrate, often most prominent in a perivascular location
- Increase in endomysial and perimysial connective tissue
- The muscle biopsy should be performed when:
- The patient presented with symptoms of muscle weakness and skin rash
- An elevated level of muscle enzymes is detected in the patient.
References
References
- ↑ Bohan, Anthony; Peter, James B. (1975). “Polymyositis and Dermatomyositis”. New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.
- ↑ Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). “Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort”. Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
- ↑ Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). “The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis”. Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). “Polymyositis and dermatomyositis”. The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). “Polymyositis–Dermatomyositis-associated Interstitial Lung Disease”. American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
